Shares of Sellas Life Sciences shifted sharply higher this week, with the stock rocketing from $8.53 to $13.47 — a 58% gain in five sessions — as two powerful narratives converged: growing speculation the company could be acquired and a final data readout from its most important clinical trial that now appears days away.

  • An SEC Filing Lit the Buyout Fuse. On June 24, Sellas amended severance and change-of-control agreements for its CEO, CFO, and chief development officer.

The updates shift change-of-control benefits to lump-sum payments and mandate immediate equity vesting upon a qualifying termination — moves the biotech sector frequently interprets as preparation for a potential acquisition. The filing landed while Merck's $6.7 billion acquisition of Terns Pharmaceuticals had already stoked takeover talk across the blood-cancer space, with several retail investors pointing to Pfizer as a potential buyer.

  • The Trial That Could Make or Break the Stock Is Almost Over. The Phase 3 REGAL trial — testing an experimental cancer vaccine in acute myeloid leukemia patients — had reached 78 of the 80 death events needed for final analysis. That count was 78 as of May 11; the 80th event triggers database lock and unblinding. The study's main goal is to determine whether the treatment leads to significant improvements in overall survival, in a population where median expected survival with standard care is less than a year. A positive result could open a path to FDA approval; a miss would gut the thesis.

  • The Balance Sheet Is Unusual for a Pre-Revenue Biotech. Sellas had $107.1 million in cash as of March 31, plus an additional $28.7 million from warrant exercises in April and May. That cash cushion makes the company a more attractive acquisition target, but it was built partly through heavy share issuance — roughly 196.6 million shares outstanding as of June 2.

  • The Stock Is Trading Far Above What Analysts Expected. At $13.47, Sellas commands a market cap near $2.6 billion — yet the average analyst one-year price target sits between $10.10 and $10.50.

Short interest stood at 63.36 million shares, or 32.65% of float, as of June 15, creating conditions for a violent squeeze or a sharp reversal once the trial data drop. Investors are making a high-conviction, binary bet — and the clock is ticking.